News

September 27, 2017

Autolus Advances New Myeloma CAR T-cell Therapy in Clinical Trial

Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two factors that drive disease in ... Read more

September 25, 2017

Bluebird and Celgene Start an Extension of Phase 1 Trial of Myeloma Therapy bb2121

News

The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to continue evaluating its safety and effectiveness, and to determine ... Read more

September 22, 2017September 22, 2017

Reolysin Combo Given to 1st Patient in Phase 1 Trial for Relapsing Myeloma

News

The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first patient, Oncolytics Biotech recently announced. ... Read more

September 20, 2017September 20, 2017

Safety Concerns Lead to Partial Hold of 2 Tecentriq Trials in Myeloma, Lymphoma

News

Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at the request of the U.S. ... Read more

September 18, 2017

Sellas’ Cancer Vaccine Galinpepimut-S Shows Durable Effects in High-risk Myeloma Patients

News

Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at the Annual Meeting of the ... Read more

September 15, 2017September 15, 2017

Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy to be used in combination ... Read more

September 13, 2017

Poseida’s Myeloma-specific CAR T-cells Combat Aggressive Cancer in Mice, Study Shows

multiple myeloma, News

Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the field of gene-edited cancer cell ... Read more

September 11, 2017September 11, 2017

Myeloma Tests Could Confuse Doctors into Suspecting Relapse, Study Argues

News

Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is having a relapse, according ... Read more

September 8, 2017

Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials

News

The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with immunomodulatory drugs as a treatment ... Read more

September 8, 2017September 10, 2017

FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths

News

The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer therapy for multiple myeloma. The ... Read more